CYTH

Cyngn earns a Neutral rating with three-out-of-five conviction, anchored by a composite score near 35. The regulatory pillar leads at 49, supported by an 80 enforcement subscore, a 50 jurisdiction posture, and no enforcement hits. Market ranks second at 40 despite unavailable institutional pricing, limiting confirmation from trading signals. Editorial contributes 30, reflecting no newsroom or brief activity in CIN newsroom coverage. Fundamentals trail at 24: exceptional gross-margin economics are outweighed by contracting revenue, severe operating losses, limited scale, and weak cash-runway scoring. The resulting pillar mix supports Neutral rather than Overweight, while the stretched financial condition prevents the regulatory lead from carrying the overall assessment higher.

Licensed fundamentals data show year-over-year revenue contraction of almost 53%, eliminating any growth contribution. Gross margin remained above 91%, earning the full gross-margin subscore, but that strength failed to translate below the gross-profit line. The operating-margin ratio was worse than negative 35 times revenue, while EBITDA was negative by approximately $24.7 million. Market capitalization stood near $23.6 million, producing a low scale subscore, and the cash-burn ratio ran slightly above one, consistent with the 15 cash-runway contribution and stretched condition. Reported net income was zero, but that figure does not offset negative EBITDA or the operating deficit. Filing cadence is the central regulatory weakness: primary regulatory filings provide no latest filing date, while disclosed regulatory-event counts remained at zero across both the 90-day and 180-day windows. That absence holds cadence at 25 even as the enforcement record scores strongly.

The clearest rerating catalyst sits inside the strongest pillar. A current primary regulatory filing would establish an observable reporting timestamp, improve cadence visibility, and reinforce the existing combination of a midrange jurisdiction posture and strong enforcement standing. Regular filings could also supply fresh operating evidence capable of testing whether the above-91% gross margin can coexist with lower cash consumption and narrower operating losses. Institutional pricing feeds currently provide no available quote, while CIN newsroom coverage contains no company-specific activity, leaving regulatory disclosure as the most direct route to stronger conviction. The single most important signal to watch is the appearance of a current primary regulatory filing that restores measurable filing cadence.